ONCY Earnings

ONCY reported its FY2025Q2 earnings on 2025-08-08, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was -0.05, surpassing the expected -0.11 by 54.55% . The stock experienced a -6.2% price change on the earnings day and a 11.46% change over the next five days, reflecting market reactions to the results.

Following ONCY's FY2025Q2 earnings announcement on 2025-08-08, the stock price moved by -6.20% on the day of the release. Over the subsequent five days, it saw a 11.46% change. Historically, ONCY's stock price tends to shift by an average of -0.77% in the 10 days leading up to earnings and -6.36% in the 10 days following, providing insight into potential market.

For , analysts estimate ONCY’s annual revenue to reach undefined, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Go Down by -12.93% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ONCY's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Go Down by -12.93% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ONCY's stock price typically moves by -0.77% in the 10 days before its earnings and -6.36% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.00 and revenue of undefined.

The earnings call presents a mixed picture: while there are positive developments like the $20 million share purchase agreement and reduced operating expenses, there are notable risks such as regulatory, clinical trial, and leadership transition uncertainties. The Q&A section reveals some vagueness in management's responses, particularly concerning the registration path for the breast cancer program. These factors, along with the ongoing net loss and market competition risks, suggest a neutral sentiment for the stock price in the short term.